Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Stephen Alloy

Psychiatry Manchester, CT Medical Doctor

NPI 1881662450 CMS profile 900726

150 N Main St, Manchester, CT 06042

Open in the dashboard

General payments

$835

13 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Stephen Alloy of Manchester, CT is reported in the CMS Open Payments database as having received $835 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $47 1
2020 General $28 2
2019 General $760 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Alloy
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Stephen Alloy were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Stephen Alloy Psychiatry median Middle half National median
2019 $760 $184 $59–$605 $163
2020 $28 $119 $36–$372 $114
2021 $47 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Allergan Inc. $229 6 payments
  2. Neurocrine Biosciences, Inc. $200 2 payments
  3. Alkermes, Inc. $125 1 payment
  4. Janssen Pharmaceuticals, Inc $115 1 payment
  5. Sunovion Pharmaceuticals Inc. $106 1 payment
  6. ITI, Inc. $60 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $788 12 payments
  2. Education $47 1 payment
Products named General payments · program years 2019–2021
  1. VRAYLAR $229 6 payments
  2. INGREZZA $200 2 payments
  3. ARISTADA Cns $125 1 payment
  4. ARISTADA Cns $125 1 payment
  5. ARISTADA Cns $125 1 payment
  6. ARISTADA Cns $125 1 payment
  7. ARISTADA INITIO $125 1 payment
  8. INVEGA SUSTENNA $115 1 payment
  9. INVEGA TRINZA $115 1 payment
  10. LATUDA $106 1 payment
  11. Other $60 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

2,585

Median for Psychiatry: 574

Drug cost

$155,116

Median for Psychiatry: $27,624

Branded share of claims

19.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 18 $40,543
Vraylar Cariprazine Hcl Brand 17 $25,837
Trintellix Vortioxetine Hydrobromide Brand 14 $17,974
Aripiprazole Generic 100 $6,300
Belsomra Suvorexant Brand 13 $5,793
Lurasidone Hcl Generic 21 $4,428
Olanzapine Generic 132 $4,367
Bupropion Xl Bupropion Hcl Brand 153 $3,953
Oxcarbazepine Generic 28 $3,817
Clozapine Generic 90 $3,795

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$8,197

Medicare's payments for the services billed

Medicare patients

60

Average age 67

Services billed

155

39 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Depression 47%
Arthritis 28%
Diabetes 27%
COPD 27%
Chronic kidney disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record